Aberdeen Group plc Trims Position in Hologic, Inc. $HOLX

Key Points

• Aberdeen Group plc reduced its stake in Hologic, Inc. by 35.7%, selling 132,130 shares and now holds approximately 0.11% of the company worth $14.69 million.
• Hologic reported earnings per share of $1.08 for its latest quarter, exceeding the consensus estimate of $1.05, with revenue of $1.02 billion, a 1.2% increase from the previous year.
• Analyst ratings for Hologic show a consensus of “Moderate Buy” with an average target price of $78.00, reflecting varied expectations from firms after recent changes in price objectives.

Aberdeen Group plc lessened its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 35.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 238,408 shares of the medical equipment provider's stock after selling 132,130 shares during the period. Aberdeen Group plc owned approximately 0.11% of Hologic worth $14,692,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Dimensional Fund Advisors LP increased its stake in Hologic by 8.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,838,656 shares of the medical equipment provider's stock valued at $175,331,000 after buying an additional 213,366 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its position in shares of Hologic by 20.3% during the 1st quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 52,214 shares of the medical equipment provider's stock valued at $3,225,000 after purchasing an additional 8,826 shares in the last quarter. E Fund Management Co. Ltd. boosted its position in shares of Hologic by 9.5% during the 1st quarter. E Fund Management Co. Ltd. now owns 5,497 shares of the medical equipment provider's stock valued at $340,000 after purchasing an additional 479 shares in the last quarter. S Bank Fund Management Ltd bought a new position in shares of Hologic during the 1st quarter valued at about $266,000. Finally, Russell Investments Group Ltd. boosted its position in shares of Hologic by 86.0% during the 1st quarter. Russell Investments Group Ltd. now owns 223,566 shares of the medical equipment provider's stock valued at $13,798,000 after purchasing an additional 103,352 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Price Performance

NASDAQ HOLX traded up $1.09 during trading on Friday, hitting $68.26. 1,545,907 shares of the company's stock were exchanged, compared to its average volume of 1,851,908. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The company has a market cap of $15.18 billion, a PE ratio of 28.32, a P/E/G ratio of 2.48 and a beta of 0.49. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The stock's 50 day moving average price is $65.90 and its two-hundred day moving average price is $62.42.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the firm posted $1.06 earnings per share. The firm's revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

HOLX has been the subject of several recent analyst reports. Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and raised their target price for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. UBS Group raised their price target on shares of Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a report on Thursday, July 31st. Stephens decreased their price target on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Wall Street Zen upgraded shares of Hologic from a "hold" rating to a "buy" rating in a report on Friday. Finally, Raymond James Financial restated an "outperform" rating and set a $71.00 price target (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $78.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.